TECH

Bio-Techne Corporation

HealthcareBiotechnologyNASDAQ

$51.68

+$4.70 (9.10%)today

Conviction

6/ 10

Fair Value$74.91

Upside+44.95%

Signal26.97

Market Cap$8.3B

52W Range$46.01–$72.16

Next EarningsMay 6

Conviction History

Conviction Changes

Mar 19, 2026, 1:08 AM5→6conviction-rescore

Premium Content

Upgrade to premium to see the full reasoning behind each conviction change.

Price History

FAIR VALUE ANALYSISMonte Carlo · 3,000 runs · 99% valid

Fair Value$15.90

Current Price$48.81

Upside / Down-67.4%

P(Undervalued)0.0%

P(20%+ Up)0.0%

P(15%+ Down)100.0%

Fair Value Distribution — percentile bands

0.0% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

32.1%/yr

±4.4% · revenue growth to justify current price

FCF-Based Reverse DCF

29.1%/yr

±3.2% · FCF growth to justify current price

THE GAP

Market pricing margin expansion or capex normalization

Premium Content

Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.

Bull Case

No analysis yet

Bear Case

No analysis yet

Research Feed

sec_10qMar 4

Conviction: unchanged

Bio-Techne Q2 2026: Organic Growth Stalled, Margins Compressing

TECH flat organic growth stalled at flat. Margin compression from unfavorable product mix. Exosome divestiture successful at improving Diagnostics segment (10.4% margin post-divestiture vs 3.9% pre). ...